The standard of care for human papillomavirus-associated oropharyngeal squamous cell carcinoma results in high cure rates; however, these therapies typically come with severe side effects. Raymond Chai, MD, FACS, is leading an innovative trial into how a test measuring circulating HPV tumor DNA in the blood can be used to de-intensify toxic therapies while maintaining high cure rates.
